2022 Annual Meeting | C119 - Rapidly Progressive Dementia

Date Wednesday 04/06/22

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives This course is designed to help clinicians when presented with a patient with a rapidly progressive dementia (RPD) or related syndrome, to understand the evaluation pathway and how it differs from that of a typical or slowly progressive dementia syndrome; develop and apply a diagnostic algorithm for various testing, including ruling out potentially reversible or curable etiologies; and provide practical framework for diagnosis of autoimmune encephalitis.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:05 AM PDT	Introduction	Outline of Course Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��
07:00 AM - 07:00 AM PDT	Speaker	Walk-in Slides Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��
07:05 AM - 08:00 AM PDT	Speaker	Prion and other non-autoimmune mediated RPDs Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��
08:00 AM - 08:05 AM PDT	Break	Stretch, Tea, Coffee
08:05 AM - 08:45 AM PDT	Speaker	Autoimmune and Antibody-mediated Causes of RPD Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��
08:45 AM - 09:00 AM PDT	Q&A	Questions and Answers Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��, Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��

Faculty Disclosures
Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��	Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��	Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to �鶹��ýӳ�� interests or activities.